<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Microbot Medical Inc — News on 6ix</title>
<link>https://6ix.com/company/microbot-medical-inc</link>
<description>Latest news and press releases for Microbot Medical Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 14 Apr 2026 18:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/microbot-medical-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835961178dffbe2df1046a3.webp</url>
<title>Microbot Medical Inc</title>
<link>https://6ix.com/company/microbot-medical-inc</link>
</image>
<item>
<title>Microbot Medical® to Highlight Commercial Achievements Leading to the Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/microbot-medical-inc/news/microbot-medicalr-to-highlight-commercial-achievements-leading-to-the-full-market-release-fmr-of-the-libertyr-endovascular-robotic-system-at-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/microbot-medical-inc/news/microbot-medicalr-to-highlight-commercial-achievements-leading-to-the-full-market-release-fmr-of-the-libertyr-endovascular-robotic-system-at-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Tue, 14 Apr 2026 18:30:00 GMT</pubDate>
<description>The presentation will be webcast live on April 15 at 10:15 a.m. ET. Continued Engagement with Healthcare Institutions Reflects Rising MomentumHINGHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will highlight recent commercial achievements leading to the recent Full Market Release (FMR) of the LIBERTY System at the 25th Annual Needham Virtual Healthcare Confere</description>
</item>
<item>
<title>Microbot Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific Meeting</title>
<link>https://6ix.com/company/microbot-medical-inc/news/microbot-medicalr-commences-full-market-release-fmr-of-the-libertyr-endovascular-robotic-system-in-the-us-at-the-society-of-interventional-radiology-sir-annual-scientific-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/microbot-medical-inc/news/microbot-medicalr-commences-full-market-release-fmr-of-the-libertyr-endovascular-robotic-system-in-the-us-at-the-society-of-interventional-radiology-sir-annual-scientific-meeting</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>Successful Execution of the Limited Market Release (LMR) Includes Adoption by Globally Recognized Healthcare Systems in the U.S. Market and Demonstrates Broad</description>
</item>
<item>
<title>Emory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®’s LIBERTY® Endovascular Robotic System</title>
<link>https://6ix.com/company/microbot-medical-inc/news/emory-healthcare-successfully-completes-robotic-peripheral-endovascular-procedures-using-microbot-medicalrs-libertyr-endovascular-robotic-system</link>
<guid isPermaLink="true">https://6ix.com/company/microbot-medical-inc/news/emory-healthcare-successfully-completes-robotic-peripheral-endovascular-procedures-using-microbot-medicalrs-libertyr-endovascular-robotic-system</guid>
<pubDate>Thu, 26 Mar 2026 12:30:00 GMT</pubDate>
<description>World’s first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH) and robotic Y-90 radioembolization mapping for liver cancer are among the robotic cases performed using the LIBERTY System, demonstrating system adoption across multiple case types ATLANTA and HINGHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Emory Healthcare has successfully completed robotic peripheral endovascular procedures — minimally invasive treatments for certain vascular conditions — using</description>
</item>
<item>
<title>Microbot Medical® Strengthens LIBERTY® Endovascular Robotic System Position with Publication of its ACCESS PVI Pivotal Study in Leading Peer-Reviewed Medical Journal</title>
<link>https://6ix.com/company/microbot-medical-inc/news/microbot-medicalr-strengthens-libertyr-endovascular-robotic-system-position-with-publication-of-its-access-pvi-pivotal-study-in-leading-peer-reviewed-medical-journal</link>
<guid isPermaLink="true">https://6ix.com/company/microbot-medical-inc/news/microbot-medicalr-strengthens-libertyr-endovascular-robotic-system-position-with-publication-of-its-access-pvi-pivotal-study-in-leading-peer-reviewed-medical-journal</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>Being Published in the Journal of Vascular and Interventional Radiology, a Premier Peer-Reviewed Journal, Speaks to the Quality and Impact of the Study</description>
</item>
<item>
<title>Microbot Medical® to Participate at the 38th Annual Roth Conference</title>
<link>https://6ix.com/company/microbot-medical-inc/news/microbot-medicalr-to-participate-at-the-38th-annual-roth-conference</link>
<guid isPermaLink="true">https://6ix.com/company/microbot-medical-inc/news/microbot-medicalr-to-participate-at-the-38th-annual-roth-conference</guid>
<pubDate>Tue, 17 Mar 2026 12:40:00 GMT</pubDate>
<description>Live Webcast of Fireside Q&A Discussion on Monday, March 23, 2026 at 4:00 pm PT as it Nears its Full Market Release of the LIBERTY® in AprilHINGHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will participate in the Roth Annual Growth Conference, being held March 22-24 in Laguna Niguel, CA. The conference is a premier event that brings together growth companies</description>
</item>
<item>
<title>Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time</title>
<link>https://6ix.com/company/microbot-medical-inc/news/microbot-medicalr-to-participate-at-the-oppenheimer-36th-annual-healthcare-medtech-and-services-conference-for-the-first-time-4</link>
<guid isPermaLink="true">https://6ix.com/company/microbot-medical-inc/news/microbot-medicalr-to-participate-at-the-oppenheimer-36th-annual-healthcare-medtech-and-services-conference-for-the-first-time-4</guid>
<pubDate>Tue, 10 Mar 2026 12:30:00 GMT</pubDate>
<description>Live Webcast on Thursday, March 19 at 8:40 am ET to Highlight the Expanding Clinical Experience with the LIBERTY® Endovascular Robotic System During the Limited Market ReleaseHINGHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will be participating at the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference, held March 16-19, 2026. This mark</description>
</item>
<item>
<title>Microbot Medical® Aligns with Recently Adopted Policy of the Largest U.S.-Based Medical Association to Expand Protection for Healthcare Professionals from Ionizing Radiation</title>
<link>https://6ix.com/company/microbot-medical-inc/news/microbot-medicalr-aligns-with-recently-adopted-policy-of-the-largest-us-based-medical-association-to-expand-protection-for-healthcare-professionals-from-ionizing-radiation</link>
<guid isPermaLink="true">https://6ix.com/company/microbot-medical-inc/news/microbot-medicalr-aligns-with-recently-adopted-policy-of-the-largest-us-based-medical-association-to-expand-protection-for-healthcare-professionals-from-ionizing-radiation</guid>
<pubDate>Wed, 04 Mar 2026 13:30:00 GMT</pubDate>
<description>LIBERTY® Endovascular Robotic System’s Capability to Reduce Radiation Exposure Appeals to Hospitals and Healthcare ProvidersHINGHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, commends the American Medical Association’s (AMA) expanding efforts to protect health care professionals from ionizing radiation. In late 2025, the AMA adopted a new policy to strengthen protections for he</description>
</item>
<item>
<title>Microbot Medical® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event</title>
<link>https://6ix.com/company/microbot-medical-inc/news/microbot-medicalr-confirms-continued-operational-and-commercial-stability-amid-current-geopolitical-event</link>
<guid isPermaLink="true">https://6ix.com/company/microbot-medical-inc/news/microbot-medicalr-confirms-continued-operational-and-commercial-stability-amid-current-geopolitical-event</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>HINGHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular</description>
</item>
<item>
<title>Tampa General Hospital is the First Health System in Florida to Adopt the LIBERTY® Endovascular Robotic System</title>
<link>https://6ix.com/company/microbot-medical-inc/news/tampa-general-hospital-is-the-first-health-system-in-florida-to-adopt-the-libertyr-endovascular-robotic-system</link>
<guid isPermaLink="true">https://6ix.com/company/microbot-medical-inc/news/tampa-general-hospital-is-the-first-health-system-in-florida-to-adopt-the-libertyr-endovascular-robotic-system</guid>
<pubDate>Tue, 24 Feb 2026 13:30:00 GMT</pubDate>
<description>Early Post-Clearance Momentum Signals Accelerated Hospital Adoption of Advanced RoboticsHINGHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that Tampa General Hospital has become the first health system in Florida to adopt LIBERTY, marking another important milestone following the Company’s recent FDA 510(k) clearance. Microbot believes that this reflects early po</description>
</item>
<item>
<title>Microbot Medical®’s LIBERTY® Endovascular Robotic System Continues to Expand Market Visibility; Being Featured at an Industry Leading Innovation Conference</title>
<link>https://6ix.com/company/microbot-medical-inc/news/microbot-medicalrs-libertyr-endovascular-robotic-system-continues-to-expand-market-visibility-being-featured-at-an-industry-leading-innovation-conference</link>
<guid isPermaLink="true">https://6ix.com/company/microbot-medical-inc/news/microbot-medicalrs-libertyr-endovascular-robotic-system-continues-to-expand-market-visibility-being-featured-at-an-industry-leading-innovation-conference</guid>
<pubDate>Thu, 19 Feb 2026 13:30:00 GMT</pubDate>
<description>Global Robotic Leaders Convene to Discuss & Highlight Surgical Advancements of the Next Decade with a Special Focus on the Endovascular SpaceHINGHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that Harel Gadot, CEO, President and Chairman, will be a featured panelist at The Surgical Disruptive Technology Summit, which is part of SAGES NBT Innovation Weekend, taking plac</description>
</item>
<item>
<title>Microbot Medical®’s LIBERTY® Endovascular Robotic System Highlighted at a Leading Vascular Disease Management Conference</title>
<link>https://6ix.com/company/microbot-medical-inc/news/microbot-medical-liberty-endovascular-robotic-133000538</link>
<guid isPermaLink="true">https://6ix.com/company/microbot-medical-inc/news/microbot-medical-liberty-endovascular-robotic-133000538</guid>
<pubDate>Thu, 12 Feb 2026 13:30:00 GMT</pubDate>
<description>International Symposium on Endovascular Therapy (ISET) Convened Key Opinion Leaders to Discuss Advancements and Future Role of Endovascular Robotics LIBERTY® Continues to Gain Commercial Traction and Exposure as Part of Its Limited Market Release (LMR) in the US HINGHAM, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that LIBERTY was featured at the International Symposium</description>
</item>
<item>
<title>Microbot Medical® to Leverage Current Users Experience of the LIBERTY® Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption</title>
<link>https://6ix.com/company/microbot-medical-inc/news/microbot-medical-leverage-current-users-133000707</link>
<guid isPermaLink="true">https://6ix.com/company/microbot-medical-inc/news/microbot-medical-leverage-current-users-133000707</guid>
<pubDate>Thu, 05 Feb 2026 13:30:00 GMT</pubDate>
<description>Participating at the Society of Interventional Oncology Conference Will Allow the Company to Share Practical Insights and Personal ExperiencesHINGHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it is attending the Society of Interventional Oncology (SIO) annual meeting, being held in Savannah, GA, February 4-8, 2026. The timing of the conference, which is during th</description>
</item>
<item>
<title>Microbot Medical Continues its 2025 Momentum; Announces Key 2026 Milestones</title>
<link>https://6ix.com/company/microbot-medical-inc/news/microbot-medical-continues-2025-momentum-133000473</link>
<guid isPermaLink="true">https://6ix.com/company/microbot-medical-inc/news/microbot-medical-continues-2025-momentum-133000473</guid>
<pubDate>Mon, 12 Jan 2026 13:30:00 GMT</pubDate>
<description>Limited Market Release (LMR) of the LIBERTY® System is on Schedule Building on Positive Customer Feedback and Growing Market Enthusiasm, the Company Prepares for Full Market Release (FMR) in Q2 HINGHAM, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, is continuing to generate significant market and new customer momentum as it enters 2026. In 2025, the Company met its milestones, inclu</description>
</item>
<item>
<title>Microbot Medical® Announces Emory University Hospital as the First Hospital in the World to Adopt the New LIBERTY® Endovascular Robotic System</title>
<link>https://6ix.com/company/microbot-medical-inc/news/microbot-medical-announces-emory-university-133000439</link>
<guid isPermaLink="true">https://6ix.com/company/microbot-medical-inc/news/microbot-medical-announces-emory-university-133000439</guid>
<pubDate>Wed, 26 Nov 2025 13:30:00 GMT</pubDate>
<description>Adoption of LIBERTY is Consistent with Emory’s Commitment to the Growing and Evolving Field of Interventional RadiologyHINGHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, announced that Emory University Hospital, a nationally recognized academic medical center in Atlanta, has become the first hospital to adopt LIBERTY for patient care. Additionally, Microbot is collaborating with</description>
</item>
<item>
<title>Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S.</title>
<link>https://6ix.com/company/microbot-medical-inc/news/microbot-medical-commences-limited-market-133000612</link>
<guid isPermaLink="true">https://6ix.com/company/microbot-medical-inc/news/microbot-medical-commences-limited-market-133000612</guid>
<pubDate>Wed, 05 Nov 2025 13:30:00 GMT</pubDate>
<description>Harel Gadot, President and CEO, Microbot Medical Announces LIBERTY® Limited Market Release Company Completes the Required Infrastructure to Support the Introduction of LIBERTY® to the U.S. Market with the Hiring of the Core Commercial Team and Establishing Logistic Partnership Interest and Overwhelmingly Positive Feedback from Physicians and Hospital Administrators at Recent Meetings Validates Limited Market Release of LIBERTY® HINGHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Microbot Medical I</description>
</item>
<item>
<title>Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S. </title>
<link>https://6ix.com/company/microbot-medical-inc/news/microbot-medicalr-commences-the-limited-market-release-of-its-libertyr-endovascular-robotic-system-in-the-us</link>
<guid isPermaLink="true">https://6ix.com/company/microbot-medical-inc/news/microbot-medicalr-commences-the-limited-market-release-of-its-libertyr-endovascular-robotic-system-in-the-us</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>Company Completes the Required Infrastructure to Support the Introduction of LIBERTY® to the U.S. Market with the Hiring of the Core Commercial Team and</description>
</item>
<item>
<title>Microbot Medical® to Commercially Debut the LIBERTY® System at The Symposium on Clinical Interventional Oncology Annual Meeting</title>
<link>https://6ix.com/company/microbot-medical-inc/news/microbot-medical-commercially-debut-liberty-123000401</link>
<guid isPermaLink="true">https://6ix.com/company/microbot-medical-inc/news/microbot-medical-commercially-debut-liberty-123000401</guid>
<pubDate>Thu, 16 Oct 2025 12:30:00 GMT</pubDate>
<description>First U.S. Based Medical Meeting Presence Post-FDA Clearance Will Allow the Company to Commercially Engage Future Potential Users of the LIBERTY® System Company Completes the Recruitment of its Commercial Leadership Team as it Remains On Track to Commence the Launch of The LIBERTY® SystemDuring Q4 of This Year HINGHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributer of the innovative LIBERTY® Endovascular Robotic System, today announced th</description>
</item>
<item>
<title>Microbot Medical® Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular Robotic System</title>
<link>https://6ix.com/company/microbot-medical-inc/news/microbot-medical-secures-u-based-123000655</link>
<guid isPermaLink="true">https://6ix.com/company/microbot-medical-inc/news/microbot-medical-secures-u-based-123000655</guid>
<pubDate>Tue, 14 Oct 2025 12:30:00 GMT</pubDate>
<description>The Experienced MedTech Logistics Provider Will Help Ensure Effective and Efficient Inventory Management and Customer Support The Company is on Track to Commence the Launch of LIBERTY® during Q4 This Year HINGHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributer of the innovative LIBERTY® Endovascular Robotic System, has partnered with a U.S. based third-party logistics (3PL) company to support the commercialization of the FDA-cleared LIBER</description>
</item>
<item>
<title>Microbot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds</title>
<link>https://6ix.com/company/microbot-medical-inc/news/microbot-medical-announces-final-closing-120000814</link>
<guid isPermaLink="true">https://6ix.com/company/microbot-medical-inc/news/microbot-medical-announces-final-closing-120000814</guid>
<pubDate>Tue, 07 Oct 2025 12:00:00 GMT</pubDate>
<description>$25.2 million in first closing, $1.2 million in second closing and $2.8 million in third and final closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term preferred investment optionsHINGHAM, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) (“Microbot” or the “Company”), today announced the third and final closing of its previously announced exercise of certain outstanding preferred inv</description>
</item>
<item>
<title>Microbot Medical® Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio</title>
<link>https://6ix.com/company/microbot-medical-inc/news/microbot-medical-receives-first-patent-130000998</link>
<guid isPermaLink="true">https://6ix.com/company/microbot-medical-inc/news/microbot-medical-receives-first-patent-130000998</guid>
<pubDate>Wed, 01 Oct 2025 13:00:00 GMT</pubDate>
<description>Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Protecting its Innovative Technology Remains a Priority and Momentum Increasing as Global Jurisdictions Acknowledge the Uniqueness of the LIBERTY System HINGHAM, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer, manufacturer and distributer of the innovative LIBERTY® Endovascular Robotic System, today announced that the Japanese Patent</description>
</item>
</channel>
</rss>